Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Clinical outcome in patients with paroxysmal or persistent atrial fibrillation receiving bepridil.

Shiga T, Suzuki A, Naganuma M, Hosaka F, Shoda M, Hagiwara N.

Circ J. 2011;75(6):1334-42.

2.

Dose-response effects of bepridil in patients with persistent atrial fibrillation monitored with transtelephonic electrocardiograms: a multicenter, randomized, placebo-controlled,double-blind study (J-BAF Study).

Yamashita T, Ogawa S, Sato T, Aizawa Y, Atarashi H, Fujiki A, Inoue H, Ito M, Katoh T, Kobayashi Y, Koretsune Y, Kumagai K, Niwano S, Okazaki O, Okumura K, Saku K, Tanabe T, Origasa H; J-BAF Investigators..

Circ J. 2009 Jun;73(6):1020-7.

3.

Contributing factors to the apparent clearance of bepridil in patients with paroxysmal or persistent atrial fibrillation: analysis using population pharmacokinetics.

Shiga T, Hashiguchi M, Naganuma M, Suzuki A, Hagiwara N.

Ther Drug Monit. 2013 Jun;35(3):367-73. doi: 10.1097/FTD.0b013e318286ec33.

PMID:
23666576
4.

Efficacy and safety of the additional bepridil treatment in patients with atrial fibrillation refractory to class I antiarrhythmic drugs.

Miyaji K, Tada H, Fukushima Kusano K, Hashimoto T, Kaseno K, Hiramatsu S, Tadokoro K, Naito S, Nakamura K, Oshima S, Taniguchi K, Ohe T.

Circ J. 2007 Aug;71(8):1250-7.

5.

Carvedilol is effective and safe in combination with bepridil for persistent atrial fibrillation and decreases the QT prolongation induced by bepridil therapy.

Kawamura M, Munetsugu Y, Tanno K, Kobayashi Y.

J Cardiovasc Pharmacol. 2013 Jan;61(1):77-82. doi: 10.1097/FJC.0b013e3182790692.

PMID:
23107870
6.

Bepridil is effective and improves QOL in multidrug-resistant paroxysmal atrial fibrillation.

Shamoto A, Chishaki A, Tsuchihashi-Makaya M, Chishaki H, Takemoto M, Mukai Y, Inoue S, Sunagawa K.

J Cardiovasc Med (Hagerstown). 2012 Nov;13(11):747-54. doi: 10.2459/JCM.0b013e3283585383.

PMID:
22914308
7.

Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter.

Yasuda M, Nakazato Y, Sasaki A, Kawano Y, Nakazato K, Tokano T, Daida H.

Circ J. 2006 Jun;70(6):662-6.

8.

Conversion and maintenance of sinus rhythm by bepridil in patients with persistent atrial fibrillation.

Nakazato Y, Yasuda M, Sasaki A, Iida Y, Kawano Y, Nakazato K, Tokano T, Mineda Y, Sumiyoshi M, Nakata Y, Daida H.

Circ J. 2005 Jan;69(1):44-8.

9.
10.

Beta-blocker decreases the increase in QT dispersion and transmural dispersion of repolarization induced by bepridil.

Yoshiga Y, Shimizu A, Yamagata T, Hayano T, Ueyama T, Ohmura M, Itagaki K, Kimura M, Matsuzaki M.

Circ J. 2002 Nov;66(11):1024-8.

11.

Effectiveness of amiodarone versus bepridil in achieving conversion to sinus rhythm in patients with persistent atrial fibrillation: a randomised trial.

Yamase M, Nakazato Y, Daida H.

Heart. 2012 Jul;98(14):1067-71. doi: 10.1136/heartjnl-2012-302017.

PMID:
22689712
12.

Usefulness and safety of bepridil in converting persistent atrial fibrillation to sinus rhythm.

Fujiki A, Tsuneda T, Sugao M, Mizumaki K, Inoue H.

Am J Cardiol. 2003 Aug 15;92(4):472-5.

PMID:
12914884
14.

Pharmacological cardioversion of persistent atrial fibrillation with and without a history of drug-resistant paroxysmal atrial fibrillation.

Fujiki A, Sakamoto T, Iwamoto J, Nishida K, Nagasawa H, Mizumaki K, Inoue H.

Circ J. 2006 Sep;70(9):1138-41.

15.

Use of bepridil in combination with Ic antiarrhythmic agent in converting persistent atrial fibrillation to sinus rhythm.

Imai S, Saito F, Takase H, Enomoto M, Aoyama H, Yamaji S, Yokoyama K, Yagi H, Kushiro T, Hirayama A.

Circ J. 2008 May;72(5):709-15.

16.
17.

Evaluation of the effect of bepridil on paroxysmal atrial fibrillation: relationship between efficacy and the f-f interval in surface ECG recordings.

Yoshida T, Niwano S, Inuo K, Saito J, Kojima J, Ikeda-Murakami K, Hara H, Izumi T.

Circ J. 2003 Jan;67(1):11-5.

18.

The relationship between the plasma concentration of bepridil and its efficacy in the treatment of atrial fibrillation in Japanese patients.

Noda K, Gotoh Y, Tanioka S, Narayama Y, Kobayashi M, Iwai S, Katoh N, Tadano K.

Biol Pharm Bull. 2012;35(5):672-6.

19.

A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study.

Pappone C, Augello G, Sala S, Gugliotta F, Vicedomini G, Gulletta S, Paglino G, Mazzone P, Sora N, Greiss I, Santagostino A, LiVolsi L, Pappone N, Radinovic A, Manguso F, Santinelli V.

J Am Coll Cardiol. 2006 Dec 5;48(11):2340-7.

20.

Bepridil prevents paroxysmal atrial fibrillation by a class III antiarrhythmic drug effect.

Yoshida T, Niwano S, Inuo K, Saito J, Kojima J, Ikeda-Murakami K, Hara H, Izumi T.

Pacing Clin Electrophysiol. 2003 Jan;26(1 Pt 2):314-7.

PMID:
12687836
Items per page

Supplemental Content

Support Center